These microenvironmental cells contribute to tumor growth, angiogenesis, invasion, metastasis, immunosuppression, and resistance to anticancer therapies; therefore, CSF-1/CSF1-R inhibitors, both alone and in combination with chemotherapy, radiotherapy, and immunotherapies, are in clinical development for several tumor types, including MM [166,167]. This evidence concerns the gene CSF1 and Miyoshi myopathy.